CRVS vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 11, 2026

CRVS

58.1
AI Score
VS
CRVS Wins

DNA

38.5
AI Score

Investment Advisor Scores

CRVS

58score
Recommendation
HOLD

DNA

39score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric CRVS DNA Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 0.0% -48.5% CRVS
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 58.1/100 38.5/100 CRVS
Profit Margin 0.0% -219.6% CRVS
Beta 1.00 1.00 Tie
AI Recommendation HOLD EXTENDED Tie

Relative Price Performance (Last 90 Days)

CRVS 1M: -10.8% · 3M: -18.5% DNA 1M: -2.5% · 3M: +34.1%

Current Technical Phase

CRVS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.1 · Price: $10.53

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.4 · Price: $9.99

Fundamentals Snapshot

Metric CRVS DNA
Market Cap — —
Forward P/E -9.9 -3.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -0.5%
Gross Margin — 0.7%
Operating Margin 0.0% -2.8%
EPS -0.62 -5.06
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CRVS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.